Search

Your search keyword '"SPADARO, Giuseppe"' showing total 901 results
Start Over Author "SPADARO, Giuseppe"
901 results on '"SPADARO, Giuseppe"'

351. Hydrogel films engineered in a mesoscopically ordered structure and responsive to ethanol vapors

Author

Dispenza, Clelia, primary, Sabatino, Maria Antonietta, additional, Alessi, Sabina, additional, Spadaro, Giuseppe, additional, D’Acquisto, Leonardo, additional, Pernice, Riccardo, additional, Adamo, Gabriele, additional, Stivala, Salvatore, additional, Parisi, Antonino, additional, Livreri, Patrizia, additional, and Busacca, Alessandro C., additional

Published
2014
Full Text
View/download PDF

355. Defect of CD2- and CD3-mediated activation pathways in T cells of atopic patients: role of interleukin 2

Author

Maria Fiammetta Romano, Giuliana Valerio, Maria Caterina Turco, Salvatore Venuta, Salvatore Formisano, ROMANO, MARIA FIAMMETTA, SPADARO, GIUSEPPE, Maria Fiammetta, Romano, Giuliana, Valerio, Maria Caterina, Turco, Spadaro, Giuseppe, Salvatore, Venuta, Salvatore, Formisano, and Romano, MARIA FIAMMETTA

Subjects
Interleukin 2, Adult, Antigens, Differentiation, T-Lymphocyte, CD3 Complex, CD3, T cell, T-Lymphocytes, Immunology, CD2 Antigens, Receptors, Antigen, T-Cell, chemical and pharmacologic phenomena, Lymphocyte Activation, medicine, Hypersensitivity, Cytotoxic T cell, Humans, Receptors, Immunologic, Interleukin 4, biology, Lymphokine, Receptors, Interleukin-2, T lymphocyte, Molecular biology, Recombinant Proteins, stomatognathic diseases, medicine.anatomical_structure, biology.protein, Interleukin-2, Interleukin-4, Cell activation, medicine.drug, Interleukin-1, Signal Transduction
Abstract

In the present work we analyzed the proliferative response of T lymphocytes from 11 atopic patients stimulated in vitro via either the CD2 or the CD3 pathway of cell activation. In both cases we found a significant decrease of thymidine incorporation in cell DNA in comparison with T cells from normal donors. The mechanism of this impaired proliferative response was analyzed. Atopic patients' T cells were found to secrete low quantities of interleukin 2 (IL2) and to express low amounts of Tac antigen, measured as both a percentage of Tac-positive cells and a mean fluorescence intensity of Tac antigen per cell. Addition of recombinant IL2 to cultures completely restored both cell proliferative response and Tac antigen expression. This effect was specific of IL2 since addition of IL1 or IL4 did not significantly affect T cell proliferative response. We conclude that atopic patients' T lymphocytes have a defect in both CD2 and CD3 pathways of cell activation relying on impairment of IL2 production, without involving IL2 responsiveness or other lymphokine defects.

Published
1992

357. Modulation of mediator release from human FcRI+ cells

Author

GENOVESE, ARTURO, SPADARO, GIUSEPPE, MARONE, GIANNI, Ciccarelli A., DE PAULIS, AMATO, Cirillo R., D. Olivieri, P. Barnes, S. Hurd, G. Folco, Genovese, Arturo, Spadaro, Giuseppe, Ciccarelli, A., DE PAULIS, Amato, Cirillo, R., and Marone, Gianni

Published
1992

358. Antiinflammatory effects of cyclosporin A

Author

MARONE, GIANNI, SPADARO, GIUSEPPE, DE PAULIS, AMATO, Ciccarelli A., Casolaro V., Cirillo R., T. Miyamoto, M. Okuda, Marone, Gianni, DE PAULIS, Amato, Ciccarelli, A., Casolaro, V., Spadaro, Giuseppe, and Cirillo, R.

Published
1992

364. Clinical Associations of Biallelic and Monoallelic TNFRSF13B Variants in Italian Primary Antibody Deficiency Syndromes.

Author

Pulvirenti, Federica, Zuntini, Roberta, Milito, Cinzia, Specchia, Fernando, Spadaro, Giuseppe, Danieli, Maria Giovanna, Pession, Andrea, Quinti, Isabella, and Ferrari, Simona

Subjects
TUMOR necrosis factors, GENE frequency, IMMUNOLOGICAL deficiency syndromes, HUMAN genetic variation, GENETIC mutation, LYMPHATIC disease diagnosis, ALLELES, AUTOANTIBODIES, B cells, GENE expression, GENES, GENETIC counseling, GENETIC polymorphisms, IMMUNITY, IMMUNOGLOBULINS, LYMPHATIC diseases, MEMBRANE proteins, GENETIC testing, CASE-control method, DIAGNOSIS
Abstract

We assessed the prevalence of TNFRSF13B mutations and the clinical correlates in an Italian cohort of 189 CVID, 67 IgAD patients, and 330 healthy controls to substantiate the role of TACI genetic testing in diagnostic workup. We found that 11% of CVID and 13% of IgAD carried at least one mutated TNFRSF13B allele. Seven per cent of CVID had monoallelic-mutations and 4% had biallelic-mutations. The frequency of C104R monoallelic-mutations was not higher than that found in healthy controls. Biallelic-mutations were exclusively found in CVID. CVID patients carrying monoallelic-mutations had an increased prevalence of lymphadenopathy, granulomata, and autoimmune cytopenias. CVID carrying biallelic-mutations had a low prevalence of autoimmunity in comparison with TACI wild-type CVID. Moreover, biallelic-mutated CVID had higher frequency of switched memory B-cells and higher IgM and IgA antibodies to polysaccharide antigens than TACI wild-type and monoallelic-mutated CVID. TACI-mutated IgAD patients had only monoallelic-mutations and did not display clinical difference from IgAD wild-type patients. In conclusion, TNFRSF13B genetic screening of antibody deficiencies may allow the identification of mutational patterns. However, as with counseling for risk assessment, geneticists should be aware that the interpretation of genetic testing for TACI mutations is difficult and the potential impact on clinical management is still limited. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

365. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study.

Author

Detoraki, Aikaterini, Di Capua, Lorena, Varricchi, Gilda, Genovese, Arturo, Marone, Gianni, and Spadaro, Giuseppe

Subjects
CHURG-Strauss syndrome, IMMUNOSUPPRESSIVE agents, FOLLOW-up studies (Medicine), EOSINOPHILIA, ASTHMA diagnosis, PATIENTS, DIAGNOSIS, THERAPEUTICS
Abstract

Objective: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis characterized by asthma and blood eosinophilia, with the lung being the organ most frequently affected. Oral glucocorticoids and/or immunosuppressive drugs are the mainstay therapy of EGPA. Occasional reports suggest that EGPA patients can be treated with omalizumab in addition to conventional therapy to achieve asthma control. To investigate the long-term effects of omalizumab in patients with EGPA and asthma (2 females, 3 males, age 41–64 years), we carried out a 36-month follow-up observational study. At the time of enrollment, the patients were on maintenance therapy and had moderate to severe allergic asthma, eosinophilia and rhinosinusitis. Mononeuropathy/polyneuropathy and/or histological evidence of tissue eosinophilic infiltration were also present.Methods: Patients were treated with omalizumab (300–600 mg s.c. every 2–4 weeks) as add-on therapy to prednisone, inhaled steroids and bronchodilators. During omalizumab treatment, spirometry, the asthma control test (ACT) score and eosinophilia were evaluated, and prednisone dosage was recorded.Results: During the 36 months of omalizumab treatment asthma progressively improved as indicated by spirometry and the ACT score. Eosinophilia progressively decreased. The oral prednisone dose was reduced or withdrawn during treatment. No adverse events were recorded.Conclusions: In patients with EGPA and moderate to severe allergic asthma, omalizumab can be beneficial and safe. It enables corticosteroid tapering while decreasing eosinophilia and improving asthma symptoms over 36 months. [ABSTRACT FROM PUBLISHER]

Published
2016
Full Text
View/download PDF

371. Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in PracticeSubstudy

Author

Louis, Renaud, Harrison, Tim W., Chanez, Pascal, Menzella, Francesco, Philteos, George, Cosio, Borja G., Lugogo, Njira L., de Luiz, Gustavo, Burden, Annie, Adlington, Timothy, Keeling, Nanna, Kwiatek, Justin, Garcia Gil, Esther, Pohl, Wolfgang, Doberer, Daniel, Martinot, Jean Benoit, Deschampheleire, Maud, Himpe, Ulrike, Chapman, Kenneth, Cheema, Amarjit, Dorscheid, Delbert, Ramsey, Clare, Rolf, Jeffrey, Walker, Brandie, Olivenstein, Ronald, Poirier, Claude, Larivee, Pierre, Bjerrum, Anne Sofie, Titlestad, Ingrid, Hilberg, Ole, Kilpeläinen, Maritta, Bonniaud, Philippe, Taillé, Camille, Tiotiu, Iuliana-Angelica, Girodet, Pierre-Olivier, Blanc, François-Xavier, Pradelli, Johana, Didier, Alain, Nocent Ejnaini, Cecilia, Deslee, Gaetan, Pison, Christophe, Douadi, Youcef, Mahay, Guillaume, Devouassoux, Gilles, Melloni, Boris, Roux, Pauline-Marie, Bourdin, Arnaud, Fry, Stephanie, Schaum, Thomas, Schulz, Christian, Skowasch, Dirk, Taube, Christian, Welte, Tobias, Gleiber, Wolfgang, Brehler, Randolf, Schreiber, Jens, Schuette, Wolfgang, Kronsbein, Juliane, Bonnet, Reiner, Beck, Ekkehard, Lacedonia, Donato, Senna, Gianenrico, Caruso, Cristiano, Crimi, Nunzio, Blasi, Francesco, Santus, Pierachille, Canonica, Giorgio Walter, Guarnieri, Gabriella, Pelaia, Girolamo, Milanese, Manlio, Micheletto, Claudio, Corsico, Angelo Guido, Scichilone, Nicola, Spadaro, Giuseppe, Langeveld, Bas, Holters, Jurgen, Willem van den Berg, Jan, Smit, Arthur, Conemans, Lennart, van Veen, Helena, Staaks, Gerald, Lehmann, Sverre, Echave-Sustaeta, Jose Maria, Ribas, Christian Domingo, de Luiz Martinez, Gustavo, Gonzalez Perez, Ruperto, Garcia Rivero, Juan Luis, Gall, Xavier Muñoz, Soto Campos, Jose Gregorio, Mozo, Paloma Campo, Pan, Carmen Vidal, Fernandez, Ana Gomez-Bastero, Tellez, Sergio Campos, Rivera, Carlos Martinez, Bobolea, Irina Diana, Guerrero, Raquel Morillo, Garcia, Ismael Ali, Rodriguez Hermosa, Juan Luis, Stenfors, Nikolai, Tunsäter, Alf, Curiac, Dan, von Garnier, Christophe, Leuppi, Joerg, Schmid-Grendelmeier, Peter, Nasser, Shuaib, Chaudhuri, Rekha, Nordstrom, Monica, Saralaya, Dinesh, Pfeffer, Paul, Mansur, Adel, Short, Philip, Wenzel, Sally, Cherry, William Brett, Zafra, Heidi, Gonzalez, Erika, Soong, Weily, Davis, Benjamin, Kao, Neil, Hussain, Iftikhar, Maselli Caceres, Diego Jose, Harris, James, Calhoun, William, Rodicio, Ileana, Kaufman, David, Moss, Mark, Sztejman, Eric, DeLeon, Samuel, Sumino, Kaharu, Kashyap, Ravindra, Leflein, Jeffrey, Hajal, Rizan, Fakih, Faisal, Hill, David, Lin, Robert, Jarratt, Mikell, Subramaniam, Vijay, Sussman, Robert, Mumneh, Nayla, Reibman, Joan, Darveaux, Jared, Tan, Ricardo, Tanus, Tonny, Sikand, Vinay, Marshall, Gailen, Mehta, Hemalini, Cole, Jeremy, Goodman, Brad, Goss, Deborah, Bardelas, Jose, Milstone, Aaron, Mehta, Vinay, Clore, Lee, Millard, Mark, Palumbo, Michael, Puppala, Dileep, Leong, Mila, Prenner, Bruce, Robinette, Emory, Heidarian Raissy, Hengameh, Fost, David, Pleskow, Warren, Marcus, Michael, Ilowite, Jonathan, Moore, Wendy, Steven, Gary, De la Cruz, Luis, Chupp, Geoffrey, Berger, William, Randolph, Christopher, Holguin, Fernando, Kureishy, Shahrukh, Campbell, Edward, Peche, Rudi, Pini, Laura, Papi, Alberto, Beghé, Bianca, Peveri, Silvia, Henriquez Santa, Aythamy, Ramos Gonzalez, Jacinto, Vinge, Ines, and St. John, Roy

Abstract

The phase IIIb, randomized, parallel-group, placebo-controlled ANDHI double-blind (DB) study extended understanding of the efficacy of benralizumab for patients with severe eosinophilic asthma. Patients from ANDHI DB could join the 56-week ANDHI in Practice(IP) single-arm, open-label extension substudy.

Published
2023
Full Text
View/download PDF

373. Proteomic Analysis of Sera from Common Variable Immunodeficiency Patients Undergoing Replacement Intravenous Immunoglobulin Therapy

Author

Spadaro, Giuseppe, primary, D'Orio, Concetta, additional, Genovese, Arturo, additional, Galeotafiore, Antonella, additional, D'Ambrosio, Chiara, additional, Di Giovanni, Stefano, additional, Vitale, Monica, additional, Capasso, Mario, additional, Lamberti, Vincenzo, additional, Scaloni, Andrea, additional, Marone, Gianni, additional, and Zambrano, Nicola, additional

Published
2011
Full Text
View/download PDF

385. Interlaminar fracture toughness behavior of electron-beam cured carbon-fiber reinforced epoxy-resin composites.

Author

Pitarresi, Giuseppe, Alessi, Sabina, Tumino, Davide, Nowicki, Andrzej, and Spadaro, Giuseppe

Subjects
ELECTRON beam curing, CARBON fiber-reinforced plastics, FRACTURE mechanics, COMPOSITE materials research, EPOXY resins, DELAMINATION of composite materials
Abstract

The work describes the preparation and physical-mechanical characterization of unidirectional CFRP panels manufactured by an electron beam curing technique. Delamination fracture toughness in Mode I and II is investigated in order to evaluate the influence of fiber-matrix adhesion strength, matrix toughness and matrix crosslinking density as determined by the radiation curing process. A matrix system comprising a DGEBA epoxy monomer and an initiator of cationic polymerization have been used, with one batch of resin mixed with a PES monomer in order to enhance matrix toughness. Curing was achieved with a pulsed 10 MeV Electron Beam accelerator. Thermally cured composite systems have also been manufactured and tested for comparison. Results from double cantilever beam and end notched flexure delamination tests have been analyzed and correlated with results from short beam shear, dynamic mechanical thermal analysis tests and SEM micrographs of delaminated surfaces. POLYM. COMPOS., 35:1529-1542, 2014. © 2013 Society of Plastics Engineers [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

394. B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies.

Author

Pulvirenti, Federica, Fernandez Salinas, Ane, Milito, Cinzia, Terreri, Sara, Piano Mortari, Eva, Quintarelli, Concetta, Di Cecca, Stefano, Lagnese, Gianluca, Punziano, Alessandra, Guercio, Marika, Bonanni, Livia, Auria, Stefania, Villani, Francesca, Albano, Christian, Locatelli, Franco, Spadaro, Giuseppe, Carsetti, Rita, and Quinti, Isabella

Subjects
PRIMARY immunodeficiency diseases, SARS-CoV-2, IMMUNOLOGIC memory, COVID-19 vaccines, COMMON variable immunodeficiency, B cells, T cells, IMMUNOGLOBULINS
Abstract

Background: Patients with primary antibody deficiencies are at risk in the current COVID-19 pandemic due to their impaired response to infection and vaccination. Specifically, patients with common variable immunodeficiency (CVID) generated poor spike-specific antibody and T cell responses after immunization. Methods: Thirty-four CVID convalescent patients after SARS-CoV-2 infection, 38 CVID patients immunized with two doses of the BNT162b2 vaccine, and 20 SARS-CoV-2 CVID convalescents later and immunized with BNT162b2 were analyzed for the anti-spike IgG production and the generation of spike-specific memory B cells and T cells. Results: Spike-specific IgG was induced more frequently after infection than after vaccination (82% vs. 34%). The antibody response was boosted in convalescents by vaccination. Although immunized patients generated atypical memory B cells possibly by extra-follicular or incomplete germinal center reactions, convalescents responded to infection by generating spike-specific memory B cells that were improved by the subsequent immunization. Poor spike-specific T cell responses were measured independently from the immunological challenge. Conclusions: SARS-CoV-2 infection primed a more efficient classical memory B cell response, whereas the BNT162b2 vaccine induced non-canonical B cell responses in CVID. Natural infection responses were boosted by subsequent immunization, suggesting the possibility to further stimulate the immune response by additional vaccine doses in CVID. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

400. Mast cell and basophil activation by human anti-IgE autoantibodies

Author

MARONE, GIANNI, SPADARO, GIUSEPPE, Casolaro V., Quinti I., Paganelli R., Stellato C., W.J. Pichler, B.M. Stadler, C.A. Dahinden, A.R. Pecoud, P. Frei, C.H. Schneider, A.L. de Weck, Marone, Gianni, Casolaro, V., Quinti, I., Paganelli, R., Spadaro, Giuseppe, and Stellato, C.

Published
1989

Catalog

Books, media, physical & digital resources
See catalog results